Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTAN5W2)

• DTT Name: Raf messenger RNA (Raf mRNA) DTT Info
• Gene Name: RAF1

Molecule-Related Drug & Molecule List

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN2480	DMBR8NF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
ICo-007	DM79W8K	Diabetic macular edema	9B71.02	Phase 1	[2]
LErafAON	DMNHPOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
LXH254	DMQE9PS	Non-small-cell lung cancer	2C25.Y	Phase 1	[4]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
SPN-803	DM8O2AQ	Parkinson disease	8A00.0	Phase 1	[1]

21 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid	DMISOLU	Discovery agent	N.A.	Investigative	[6]
6-Benzylsulfanyl-9H-purine	DMI7FNZ	Discovery agent	N.A.	Investigative	[7]
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	DMDNG8F	Discovery agent	N.A.	Investigative	[7]
DEBROMOHYMENIALDISINE	DMDLER8	Discovery agent	N.A.	Investigative	[8]
GW-5074	DMIHOYF	Discovery agent	N.A.	Investigative	[9]
ISIS 10707	DMYG5IO	Discovery agent	N.A.	Investigative	[10]
ISIS 11061	DMNKY2R	Discovery agent	N.A.	Investigative	[10]
ISIS 15770	DMJCXHM	Solid tumour/cancer	2A00-2F9Z	Investigative	[11]
ISIS 6717	DM5KGQO	Discovery agent	N.A.	Investigative	[10]
ISIS 6720	DMJS6B0	Discovery agent	N.A.	Investigative	[10]
ISIS 6729	DMWZOQJ	Discovery agent	N.A.	Investigative	[10]
ISIS 7847	DMTN1D7	Discovery agent	N.A.	Investigative	[10]
ISIS 7848	DMOXBDT	Discovery agent	N.A.	Investigative	[10]
ISIS 7849	DMQYB7A	Discovery agent	N.A.	Investigative	[10]
ISIS 7851	DMJKC45	Discovery agent	N.A.	Investigative	[10]
ISIS 7853	DM12E76	Discovery agent	N.A.	Investigative	[10]
ISIS 7855	DMKAQ6U	Discovery agent	N.A.	Investigative	[10]
ISIS 9058	DMD1MEZ	Discovery agent	N.A.	Investigative	[10]
L-790070	DMJKAQR	Autoimmune diabetes	5A10	Investigative	[12]
PLX-ORI3	DMZG1L5	Solid tumour/cancer	2A00-2F9Z	Investigative	[1]
ZM-336372	DMD5JYQ	Discovery agent	N.A.	Investigative	[13]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
• [2] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [3] Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Roche.
• [6] Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5378-83.
• [7] Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
• [8] Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
• [9] Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
• [10] US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
• [11] US patent application no. 7,425,545, Modulation of C-reactive protein expression.
• [12] Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of ... J Med Chem. 2008 Jul 24;51(14):4122-49.
• [13] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.